Deubiquitylation of Rab35 by USP32 promotes the transmission of imatinib resistance by enhancing exosome secretion in gastrointestinal stromal tumours-Reference-Cited by-同舟云学术

Deubiquitylation of Rab35 by USP32 promotes the transmission of imatinib resistance by enhancing exosome secretion in gastrointestinal stromal tumours

Published:2023-02-01 Issue:12 Volume:42 Page:894-910
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Li Chao^ORCID,Gao Zhishuang,Cui Zhiwei^ORCID,Liu Zonghang,Bian Yibo,Sun Haoyu,Wang Nuofan,He Zhongyuan,Li Bowen,Li Fengyuan,Li Zheng,Wang Linjun,Zhang Diancai,Yang Li,Xu Zekuan^ORCID,Xu Hao^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

https://www.nature.com/articles/s41388-023-02600-1.pdf

Reference48 articles.

1. Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol. 2022;19:328–41.

2. Serrano C, George S. Gastrointestinal stromal tumor: challenges and opportunities for a new decade. Clin Cancer Res. 2020;26:5078–85.

3. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–78.

4. Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer. 2011;129:2533–42.

5. Farag S, van Coevorden F, Sneekes E, Grunhagen DJ, Reyners AKL, Boonstra PA, et al. Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients. Eur J Cancer. 2017;86:318–25.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extracellular Vesicles from Compression‐Loaded Cementoblasts Promote the Tissue Repair Function of Macrophages;Advanced Science;2024-08-05

2. RAB42 overexpression correlates with poor prognosis, immune cell infiltration and chemoresistance;Frontiers in Pharmacology;2024-07-19

3. USP32 facilitates non-small cell lung cancer progression via deubiquitinating BAG3 and activating RAF-MEK-ERK signaling pathway;Oncogenesis;2024-07-19

4. Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options;Molecular Cancer;2024-05-03

5. USP32 facilitates non-small cell lung cancer progression via deubiquitinating BAG3 and activating RAF-MEK-ERK signaling pathway;2024-02-05